Surrogate End Points: How Well do They Represent Patient-relevant End Points?

• Ackermann BL , HaleJE, DuffinKL: The role of mass spectrometry in biomarker discovery and measurement.Curr. Drug Metab.7(5), 525–539 (2006).
   PubMed Web of Science ®Google Scholar
• Rifai N , GilletteMA, CarrSA: Protein biomarker discovery and validation: the long and uncertain path to clinical utility.Nat. Biotechnol.24(8), 971–983 (2006).
   PubMed Web of Science ®Google Scholar
• Servais AC , CrommenJ, FilletM: Capillary electrophoresis-mass spectrometry, an attractive tool for drug bioanalysis and biomarker discovery.Electrophoresis27(13), 2616–2629 (2006).
   PubMed Web of Science ®Google Scholar
• Biomarkers D efinitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HoosenS, BelloCL, ChristensenJG: Sunitinib malate for the treatment of solid tumours: a review of current clinical data.Expert Opin. Investig. Drugs15(5), 553–561 (2006).
   PubMed Web of Science ®Google Scholar
• Amprenavir approved. STEP. Perspect.99(2), 8 (1999).
   Google Scholar
• Grimes DA , SchulzKF: Surrogate end points in clinical research: hazardous to your health.Obstet. Gynecol.105 (Suppl. 5 Pt 1) , 1114–1118 (2005).
   PubMed Web of Science ®Google Scholar
• Dormandy JA , CharbonnelB, EcklandDJet al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Fisler R , ScarosO: Biomarkers in clinical development: implications for personalized medicine and streamlining R&D.CHA Advances Reports,47 (2005).
   Google Scholar
• Holodniy M : HIV-1 load quantitation: a 17-year perspective.J. Infect. Dis.194 (Suppl. 1) , S38–S44 (2006).
   PubMed Web of Science ®Google Scholar
• Low A , MarkowitzM: Predictors of response to highly active antiretroviral therapy.AIDS Read.16(8), 425–428, 430–431, 434, 436 (2006).
   PubMedGoogle Scholar
• May MT , SterneJA, CostagliolaDet al.: HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.Lancet368(9534), 451–458 (2006).
   PubMed Web of Science ®Google Scholar
• DeSimone JA , PomerantzRJ, BabinchakTJ: Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.Ann. Intern. Med.133(6), 447–454 (2000).
   PubMed Web of Science ®Google Scholar
• Hughes TP , KaedaJ, BranfordSet al.: Frequency of major molecular responses to imatinib or interferon α-plus cytarabine in newly diagnosed chronic myeloid leukemia.N. Engl. J. Med.349(15), 1423–1432 (2003).
   PubMed Web of Science ®Google Scholar
• Dagher R , JohnsonJ, WilliamsG, KeeganP, PazdurR: Accelerated approval of oncology products: a decade of experience.J. Natl Cancer Inst.96(20), 1500–1509 (2004).
   PubMedGoogle Scholar
• Johnson JR , WilliamsG, PazdurR: End points and United States Food and Drug Administration approval of oncology drugs.J. Clin. Oncol.21(7), 1404–1411 (2003).
   PubMed Web of Science ®Google Scholar
• Bross PF , KaneR, FarrellATet al.: Approval summary for bortezomib for injection in the treatment of multiple myeloma.Clin. Cancer Res.10 (Suppl. 12 Pt 1) , 3954–3964 (2004).
   PubMed Web of Science ®Google Scholar
• Kane RC , FarrellAT, SridharaR, PazdurR: United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.Clin. Cancer Res.12(10), 2955–2960 (2006).
   PubMed Web of Science ®Google Scholar
• Jeffcoate SL : Diabetes control and complications: the role of glycated haemoglobin, 25 years on.Diabet. Med.21(7), 657–665 (2004).
   PubMed Web of Science ®Google Scholar
• Nakamura H , ArakawaK, ItakuraHet al.: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.Lancet368(9542), 1155–1163 (2006).
   PubMed Web of Science ®Google Scholar
• Schaefer JR , HerzumM, MaischB: Prevention of coronary heart disease–’evidence-based medicine‘ of antilipemic therapy.Herz24(1), 3–12 (1999).
   PubMed Web of Science ®Google Scholar
• Petitti D : Commentary: hormone replacement therapy and coronary heart disease: four lessons.Int. J. Epidemiol.33(3), 461–463 (2004).
   PubMed Web of Science ®Google Scholar
• Rossouw JE , AndersonGL, PrenticeRL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women‘s Health Initiative randomized controlled trial. JAMA288(3), 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet2(8403), 600–604 (1984).
   PubMed Web of Science ®Google Scholar
• Furberg CD , PittB: Withdrawal of cerivastatin from the world market.Curr. Control Trials Cardiovasc. Med.2(5), 205–207 (2001).
   PubMedGoogle Scholar
• Bots ML : Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies.Curr. Med. Res. Opin.22(11), 2181–2190 (2006).
   PubMed Web of Science ®Google Scholar
• Espeland MA , O‘learyDH, TerryJGet al.: Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors.Curr. Control Trials Cardiovasc. Med.6(1), 3 (2005).
   PubMedGoogle Scholar
• McKenney JM , DavidsonMH, ShearCL, RevkinJH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.J. Am. Coll. Cardiol.48(9), 1782–1790 (2006).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE , DahlofB, DevereuxRBet al.: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.JAMA288(12), 1491–1498 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlof B , DevereuxRB, KjeldsenSEet al.: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet359(9311), 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Piller LB , DavisBR, CutlerJAet al.: Validation of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) participants assigned to doxazosin and chlorthalidone.Curr. Control Trials Cardiovasc. Med.3(1), 10 (2002).
   PubMedGoogle Scholar
• Cohen JS : Risks of troglitazone apparent before approval in USA.Diabetologia49(6), 1454–1455 (2006).
   PubMed Web of Science ®Google Scholar
• Gale EA : Troglitazone: the lesson that nobody learned?Diabetologia49(1), 1–6 (2006).
   PubMed Web of Science ®Google Scholar
• Mühlhauser I , MeyerG: Evidence based medicine: Widersprüche zwischen Surrogatergebnissen und klinischen Endpunkten.Psychother. Psychosom. Med. Psychol.56(5), 193–201 (2006).
   PubMedGoogle Scholar
• Warren MP : A comparative review of the risks and benefits of hormone replacement therapy regimens.Am. J. Obstet. Gynecol.190(4), 1141–1167 (2004).
   PubMed Web of Science ®Google Scholar
• Baker SG , KramerBS: A perfect correlate does not a surrogate make.BMC Med. Res. Methodol.3 , 16 (2003).
   PubMedGoogle Scholar
• Fleming TR , DeMetsDL: Surrogate end points in clinical trials: are we being misled?Ann. Intern. Med.125(7), 605–613 (1996).
   PubMed Web of Science ®Google Scholar
• Prentice RL : Surrogate endpoints in clinical trials: definition and operational criteria.Stat. Med.8(4), 431–440 (1989).
   PubMed Web of Science ®Google Scholar
• Thompson IM , PaulerDK, GoodmanPJ et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N. Engl. J. Med.350(22), 2239–2246 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson IM , AnkerstDP, ChiCet al.: Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.JAMA294(1), 66–70 (2005).
   PubMed Web of Science ®Google Scholar
• Wilt TJ , ThompsonIM: Clinically localised prostate cancer.BMJ333(7578), 1102–1106 (2006).
   PubMedGoogle Scholar
• Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys.37(5), 1035–1041 (1997).
   PubMed Web of Science ®Google Scholar
• Roach M III , HanksG, ThamesHJret al.: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys.65(4), 965–974 (2006).
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L , DjavanWB, HammererPet al.: Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.Int. J. Clin. Pract.58(4), 382–390 (2004).
   PubMed Web of Science ®Google Scholar
• Collette L , BurzykowskiT, CarrollKJet al.: Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.J. Clin. Oncol.23(25), 6139–6148 (2005).
   PubMed Web of Science ®Google Scholar
• Collette L , BurzykowskiT, SchroderFH: Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.Eur. J. Cancer42(10), 1344–1350 (2006).
   PubMed Web of Science ®Google Scholar
• Fleming MT , MorrisMJ, HellerG, ScherHI: Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat. Clin. Pract. Oncol.3(12), 658–667 (2006).
   PubMedGoogle Scholar
• Buyse M , MolenberghsG: Criteria for the validation of surrogate endpoints in randomized experiments.Biometrics54(3), 1014–1029 (1998).
   PubMed Web of Science ®Google Scholar
• Molenberghs G , BuyseM, BurzykowskiT: The history of surrogate endpoint validation. In: The Evaluation of Surrogate Endpoints. Burzykowski T (Ed.). Springer Science and Business Media, Inc., NY, USA, 67–82 (2005).
   Google Scholar
• Buyse M , MolenberghsG, BurzykowskiT, RenardD, GeysH: The validation of surrogate endpoints in meta-analyses of randomized experiments.Biostatistics1(1), 49–67 (2000).
   PubMedGoogle Scholar
• Molenberghs G , BuyseM, BurzykowskiT: A meta-analytic validation framework for continuous outcomes. In: The Evaluation of Surrogate Endpoints. Burzykowski T (Ed.), Springer Science and Business Media, Inc., NY, USA, 95–120 (2005).
   Google Scholar
• deVera IE , KatzJE, AgusDB: Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery.Clin. Adv. Hematol. Oncol.4(7), 541–549 (2006).
   PubMedGoogle Scholar
• Schlotterbeck G , RossA, DieterleF, SennH: Metabolic profiling technologies for biomarker discovery in biomedicine and drug development. Pharmacogenomics7(7), 1055–1075 (2006).
   PubMed Web of Science ®Google Scholar
• Schulte I , TammenH, SelleH, Schulz-KnappeP: Peptides in body fluids and tissues as markers of disease.Expert Rev. Mol. Diagn.5(2), 145–157 (2005).
   PubMed Web of Science ®Google Scholar
• Weissinger EM , MischakH, GanserA, HertensteinB: Value of proteomics applied to the follow-up in stem cell transplantation.Ann. Hematol.85(4), 205–211 (2006).
   PubMed Web of Science ®Google Scholar
• Weissinger EM , Nguyen-KhoaT, FumeronCet al.: Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics6(3), 993–1000 (2006).
   PubMed Web of Science ®Google Scholar
• Jost M , BuddeP, TammenH, Schulz-KnappeP: Peptidomics based protease inhibitor profiling. In: Peptidomics in Drug Development. Gaenshirt D (Ed.). Editio Cantor Verlag, Aulendorf, Germany, 65–73 (2005).
   Google Scholar
• Davies SM : Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?Hematology Am. Soc. Hematol. Educ. Program111–117 (2006).
   PubMedGoogle Scholar
• Huang SM , GoodsaidF, RahmanA, FruehF, LeskoLJ: Application of pharmacogenomics in clinical pharmacology. Toxicol. Mech. Methods,1689–1699 (2006).
   Web of Science ®Google Scholar
• Bucher HC , GuyattGH, CookDJ, HolbrookA, McAlisterFA: Users‘ guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group.JAMA282(8), 771–778 (1999).
   PubMed Web of Science ®Google Scholar
• Casas JP , ChuaW, LoukogeorgakisSet al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.Lancet366(9502), 2026–2033 (2005).
   PubMed Web of Science ®Google Scholar
• Filler G , BokenkampA, HofmannWet al.: Cystatin C as a marker of GFR – history, indications, and future research.Clin. Biochem.38(1), 1–8 (2005).
   PubMed Web of Science ®Google Scholar
• Stevens LA , LeveyAS: Measurement of kidney function.Med. Clin. North Am.89(3), 457–473 (2005).
   PubMed Web of Science ®Google Scholar
• Westhuyzen J : Cystatin C: a promising marker and predictor of impaired renal function.Ann. Clin. Lab. Sci.36(4), 387–394 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes T , DeiningerM, HochhausAet al.: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.Blood108(1), 28–37 (2006).
   PubMed Web of Science ®Google Scholar
• Desai M , StockbridgeN, TempleR: Blood pressure as an example of a biomarker that functions as a surrogate.AAPS J.8(1), E146–E152 (2006).
   PubMed Web of Science ®Google Scholar
• Echt DS , LiebsonPR, MitchellLBet al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial.N. Engl. J. Med.324(12), 781–788 (1991).
   PubMed Web of Science ®Google Scholar
• Peters RW , MitchellLB, BrooksMMet al.: Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the cardiac arrhythmia suppression trial (CAST).J. Am. Coll. Cardiol.23(2), 283–289 (1994).
   PubMed Web of Science ®Google Scholar

Websites

• Food and Drug Administration: Innovation or stagnation: challenge and opportunity on the critical path to new medical products (2004). www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
   Google Scholar
• Napoli M, Norsigian J, Brenner B, Batt S, Forter D, Pearson C: Letter To FDA Commissioner McClellan Opposing Use of Surrogate Endpoints for Approval of Cancer Prevention Drugs (2003). www.medicalconsumers.org/pages/Letter%20To%20FDA–Approval%20of%20Cancer%20Prevention%20Drugs.html
   Google Scholar
• Institute for Quality and Efficiency in Health Care: methods. Version 2.0 (2007) www.iqwig.de/download/Methods_a_second_Version_Produced_by_the_Institutes_Steering_Committee.pdf
   Google Scholar
• Linda Bren: The Importance of Patient-Reported Outcomes. It‘s All About the Patients. FDA Consumer Magazine. 40(6), (2006) www.fda.gov/fdac/features/2006/606_patients.html
   Google Scholar
• Food and Drug Administration: Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (2006) www.fda.gov/cder/guidance/5460dft.pdf
   Google Scholar
• Food and Drug Administration: NDAs Approved Under Subpart H (2006). www.fda.gov/cder/rdmt/accappr.htm
   Google Scholar
• Food and Drug Administration: Pfizer Stops All Torcetrapib Clinical Trials in Interest of Patient Safety (2006). www.fda.gov/bbs/topics/NEWS/2006/NEW01514.html
   Google Scholar
• O‘Riordan M: Torcetrapib torpedoed: increased risk of mortality, cardiovascular events ends development. Heartwire (2006). www.medscape.com/viewarticle/548725
   Google Scholar
• Janis Kelly: Harsh criticism lobbed at FDA in Senate Vioxx hearing Medscape Medical News (2004). www.medscape.com/viewarticle/538021
   Google Scholar
• Food and Drug Administration: Fast Track, Accelerated Approval and Priority Review (2006). www.fda.gov/oashi/fast.html
   Google Scholar
• IQWiG. Nutzenbewertung der interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom. Abschlussbericht N04–02. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2007). www.iqwig.de/download/N04–02_Abschlussbericht_Brachytherapie.pdf
   Google Scholar
• IQWiG. Interstitial brachytherapy in localised prostate cancer. Executive Summary. IQWiG Reports. Commission No.N04–02. (2007). www.iqwig.de/download/N04–02_Executive_summary_Brachytherapy.pdf
   Google Scholar
• Food and Drug Administration: Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2007). www.fda.gov/cder/guidance/7478fnl.pdf
   Google Scholar
• Food and Drug Administration: FDA Proposes Rules Overhaul to Expand Availability of Experimental Drugs (2006). www.fda.gov/bbs/topics/NEWS/2006/NEW01520.html
   Google Scholar
• Southwest Oncology Group, National Cancer Institute (NCI), Eastern Cooperative Oncology Group: A Phase IIb Study Of Molecular Responses To Imatinib At Standard Or Increased Doses For Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase (2006). www.clinicaltrials.gov/ct/show/NCT00070499?order=1
   Google Scholar